## JBL: Jabil Inc. - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.4% in mid entry zone (3.0-6.0%), top 8% cross-sectional ranking. Short-term MRS_5 (3.2%) confirms momentum alignment. Strong momentum (+3.4% 5-day acceleration). Outperforming sector by 4.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($210.00)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. SANM's Robust Portfolio Fueling Revenues: Will the Trend Persist?**
- Source: www.sharewise.com | 20251206T050247 | Somewhat-Bullish | Relevance: 74%
-  Sanmina Corporation (SANM) is experiencing strong revenue growth, driven by its comprehensive portfolio and robust demand across various sectors. The company's diversified market presence and focus on high-growth industries are key to its resilience and continued expansion. Sanmina currently holds a Zacks Rank #1 (Strong Buy) with increasing earnings estimates for 2025 and 2026.

**2. CLS Stock Surges 260% in a Year: Can It Sustain This Growth Pace?**
- Source: TradingView | 20251208T160924 | Somewhat-Bullish | Relevance: 62%
-  Celestica Inc. (CLS) shares have surged 259.6% over the past year, significantly outperforming the industry, driven by strong demand for AI/ML compute and networking products from hyperscale customers. The company is actively expanding its offerings through new product launches, such as the SD6300 storage platform and new 1.6TbE data center switches, and has diversified its customer base across multiple industries. With positive earnings estimate revisions, a raised 2025 guidance, and a Zacks Rank #1 (Strong Buy), Celestica appears well-positioned for continued growth.

**3. Ocular Therapeutix stock hits 52-week high at 14.79 USD**
- Source: Investing.com | 20251208T144425 | Somewhat-Bullish | Relevance: 60%
-  Ocular Therapeutix (OCUL) stock reached a 52-week high of $15.07, demonstrating significant growth with a 30.77% return over the past year and 47.31% year-to-date. The biotechnology company, with a $2.68 billion market cap and strong balance sheet, is advancing its product pipeline, including an NDA for AXPAXLI, leading analysts to maintain bullish ratings and increased price targets despite current overvaluation concerns.

**4. Dodge & Cox Sells 2,638,596 Shares of Anheuser-Busch InBev SA/NV $BUD**
- Source: MarketBeat | 20251206T051159 | Somewhat-Bullish | Relevance: 58%
- Dodge & Cox reduced its stake in Anheuser-Busch InBev SA/NV (NYSE:BUD) by 6.4% in the second quarter, selling over 2.6 million shares. The institutional investor now holds 38,477,542 shares, valued at approximately $2.64 billion, making it their 27th largest holding. Anheuser-Busch InBev reported quarterly EPS of $0.99, beating estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $72.00.

**5. 5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)**
- Source: Finviz | 20251208T140800 | Somewhat-Bullish | Relevance: 58%
-  While insiders are selling shares in five key tech stocks—CoreWeave, Seagate Technology, Tempus AI, Credo Technology, and Jabil Inc.—this activity is largely due to portfolio management, diversification, and previous stock appreciation. Institutions and analysts are actively buying these high-quality tech names, forecasting significant gains. The article suggests that despite insider selling, these stocks are poised for growth over the next two to four quarters.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.00M) |
| Sells | 50 ($12.50M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.1%)
- Blackrock Inc.: 9.0% (+2.1%)
- Texas Yale Capital C: 6.0% (-0.1%)
- State Street Corpora: 4.9% (+0.7%)
- Wellington Managemen: 4.1% (-30.7%)

### Key Risks

1. Heavy insider selling: $13M sold (50 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%). Insider selling cluster ($12.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.2B |
| Beta | 1.26 |
| 52W Range | $108.66 - $237.14 |
| Short Interest | 4.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 17.5 |
| Current P/E | 20.3 |
| YoY Growth | 16.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.0% to 5.4% (+3.4% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 92nd percentile. MRS_5 at 3.2% confirms short-term momentum alignment. Outperforming sector by 4.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.56), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.39% (CS: 92) | Strong |
| RSI_14 | 66.0 | Neutral |
| MACD Histogram | 2.56 | Bullish |
| vs SMA20 | 1.085x | Above |
| vs SMA50 | 1.079x | Above |
| vs SMA200 | 1.195x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $225.42
- **Stop Loss:** $210.00 (6.8% risk)
- **Target:** $248.55 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 77
- **Position Value:** $17,357.34
- **Portfolio %:** 17.36%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

### Earnings

**Next:** 2025-12-17 (Est: $2.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.95 | $3.29 | +11.7% |
| 2025Q2 | $2.32 | $2.55 | +9.8% |
| 2025Q1 | $1.83 | $1.94 | +6.2% |
| 2024Q4 | $1.88 | $2.00 | +6.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*